Clinical trialNCT03778229Active, not recruitingPhase 2Interventional

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

SponsorAstraZenecaEnrollment367Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Lecia V Sequist, MD MPH
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗
Myung-Ju Ahn, MD
Samsung Medical Centre Sungkyunkwan University School of Medicine
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

90 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Research Site
Barretos, Brazil
Research Site
Curitiba, Brazil
Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Canada

Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada

Chile

Research Site
Santiago, Chile
Research Site
Santiago, Chile
Research Site
Santiago, Chile

Denmark

Research Site
Aalborg, Denmark
Research Site
Herlev, Denmark
Research Site
København Ø, Denmark
Research Site
Næstved, Denmark
Research Site
Odense, Denmark
Research Site
Vejle, Denmark

France

Research Site
Dijon, France
Research Site
Marseille, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Paris, France
Research Site
Rennes, France

India

Research Site
Bangalore, India
Research Site
Chennai, India
Research Site
Kolkata, India
Research Site
New Delhi, India

Italy

Research Site
Avellino, Italy
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Orbassano, Italy

50 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Osimertinib →PlaceboSavolitinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Jan 2019
Primary completion: 23 Aug 2024
Completion: 31 Dec 2026
Last update posted: 23 Apr 2026
Registered enrollment: 367
Registry id: NCT03778229

Cross-registrations

EU-CTR / CTIS (EudraCT)2018-003012-51

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.